Ironwood Pharma (IRWD) Tops Q1 EPS by 3c, Revenues Miss; Offers FY21 Revenues Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Ironwood Pharma (IRWD) Tops Q1 EPS by 3c, Revenues Miss; Offers FY21 Revenues Guidance Above Consensus
May 6, 2021 7:03 AM EDT
BOSTON--(BUSINESS WIRE)--
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that its Board of Directors has authorized a new share repurchase program under which the Company may repurchase up to $150 million of its outstanding shares of common stock through December 2022.
Ironwood maintains a disciplined and thoughtful... More
May 6, 2021 7:00 AM EDT
LINZESS® (Iinaclotide) U.S. net sales of $215 million, an increase of 12% year-over-year
Total revenue of $89 million, an increase of 11% year-over-year, driven primarily by U.S. LINZESS collaboration revenue of $86 million
GAAP net income of $40 million and adjusted EBITDA of $46 million; ended Q1 2021 with $438 million in cash and cash equivalents
Maintaining full year 2021 financial guidance
BOSTON--(BUSINESS... More
